skip to main content

Antitrust matters are rarely isolated within a single state or federal agency or jurisdiction. We represent clients facing multi-dimensional antitrust challenges on the transactional, regulatory and litigation fronts, mobilizing an unmatched combination of courtroom excellence, government experience and legal, economic and academic prowess on our clients’ behalf.

Cigna to Acquire Express Scripts for $67 Billion

Paul, Weiss is advising Cigna Corporation in the regulatory aspects of its pending acquisition of Express Scripts Holding Company. Under the agreement, Cigna will acquire Express Scripts in a cash and stock transaction valued at approximately $67 billion, including Cigna's assumption of approximately $15 billion in Express Scripts debt. The merger consideration will consist of $48.75 in cash and 0.2434 shares of stock of the combined company per Express Scripts share. The transaction was approved by the board of directors of each company.

The Paul, Weiss team acting as regulatory counsel to Cigna includes litigation partners Rick Rule and Andrew Forman and counsel Daniel Howley and Marta Kelly.

March 8, 2018

© 2020 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy